Dean Rudge

1 week ago | insights.citeline.com | Dean Rudge

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience ContinuesTyenne Biosimilar At 22% Share In Europe And 8% In US; Transfer ‘Will Take Time’Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.

1 week ago | insights.citeline.com | Dean Rudge

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ ClaimsTrial Was Set To Begin 19 May; Jazz Pharma Agreed Settlement Last Month For $145mHikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

1 week ago | insights.citeline.com | Dean Rudge

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent CaseSettlement Permits Launches Of Two ANDA Products From June 2032; Kabi Has Appealed JudgmentViatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.

1 week ago | insights.citeline.com | Dean Rudge

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab CompetitionRecent Launches Including Aflibercept And Ustekinumab Push Sales Up By 35%Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.

1 week ago | insights.citeline.com | Dean Rudge

Viatris Agrees To $335m Opioid Settlement Ending US State, Local Government Cases Viatris joined Hikma and Amneal, in signing agreements for cash settlements that resolve allegations its practices fueled the US’ deadly opioid epidemic. Viatris will make annual payments over nine years as part of the settlement. • Source: Shutterstock